Supramolecular Anti-Infectives

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (30 June 2020) | Viewed by 4849

Special Issue Editor


E-Mail Website
Guest Editor
LMI CNRS UMR 5615, Université Lyon 1, 69622 Villeurbanne, France
Interests: biomechanics; silver nanoparticle antibiotic action; metal ions in epigenetics; bioactive supramolecular systems; 3D printing and biofilms
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In world in which the types and nature of infective agents are changing rapidly and for which our definition of infective is being changed by concepts such as epigenetics and data mining, we are searching for new agents to combat infection and are now looking outside classical pharmaceutical agents. Thus, the time may have arrived to look at how supramolecular systems are emerging in the treatment of all types of infection.

For this Special Issue, it is best to first define the title. Regarding ‘’Supramolecular’’, we will consider any molecular assembly, other than colloidal systems, that is held together by non-covalent bonding as being supramolecular. Anti-infectives can be defined as Active Pharmaceutical Ingredients that act against invasive disease causing agents. Thus, we will be happy to see papers on anti-virals, anti-bacterials, and fungicidal and anti-parasitic agents, but also on epigenetic agents. Supramolecular systems can act as excipients; co-crystal formers; API transporters; or, more interestingly, as APIs themselves.

In terms of the study, all aspects of the subject are welcome, from structural studies of supramolecular API complexes through biochemical studies to clinical studies. Subjects at the edge of the definitions are particularly welcomed; these could include new technologies such as 3D printing as long as there is a supramolecular anti-infective involved.

Thus, the subject is wide open within the one above limits!

Prof. Dr. Anthony Coleman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Active Pharmaceutical Ingredients
  • Anti-virals
  • anti-bacterials
  • fungicidal agents
  • anti-parasitic agents
  • Epigenetic agents
  • Supramolecular systems,excipients
  • co-crystal formers
  • API transporters
  • Supramolecular APIs
  • structure
  • biochemical activity
  • cytotoxicity
  • in-vivo activity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 3019 KiB  
Article
Size and Flexibility Define the Inhibition of the H3N2 Influenza Endonuclease Enzyme by Calix[n]arenes
by Yannick Tauran, José Pedro Cerón-Carrasco, Moez Rhimi, Florent Perret, Beomjoon Kim, Dominique Collard, Anthony W. Coleman and Horacio Pérez-Sánchez
Antibiotics 2019, 8(2), 73; https://doi.org/10.3390/antibiotics8020073 - 3 Jun 2019
Cited by 4 | Viewed by 4095
Abstract
Inhibition of H3N2 influenza PA endonuclease activity by a panel of anionic calix[n]arenes and β-cyclodextrin sulfate has been studied. The joint experimental and theoretical results reveal that the larger, more flexible and highly water-soluble sulfonato-calix[n]arenes have high inhibitory activity, with para-sulfonato-calix[8]arene, SC8, having [...] Read more.
Inhibition of H3N2 influenza PA endonuclease activity by a panel of anionic calix[n]arenes and β-cyclodextrin sulfate has been studied. The joint experimental and theoretical results reveal that the larger, more flexible and highly water-soluble sulfonato-calix[n]arenes have high inhibitory activity, with para-sulfonato-calix[8]arene, SC8, having an IC50 value of 6.4 μM. Molecular docking calculations show the SC8 can interact at both the polyanion binding site and also the catalytic site of H3N2 influenza PA endonuclease. Full article
(This article belongs to the Special Issue Supramolecular Anti-Infectives)
Show Figures

Figure 1

Back to TopTop